Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 10 IN PLASTIC CONTAINER versus DEXTROSE 7 7 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: DEXTROSE 10 IN PLASTIC CONTAINER versus DEXTROSE 7 7 IN PLASTIC CONTAINER.
DEXTROSE 10% IN PLASTIC CONTAINER vs DEXTROSE 7.7% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intravenous dextrose provides a source of calories and water for hydration. Dextrose is metabolized to carbon dioxide and water, yielding energy (approximately 3.4 kcal/g). It also stimulates insulin secretion and promotes glycogen synthesis.
Dextrose is a simple sugar that provides a source of calories and fluid for intravenous administration. It increases blood glucose levels, enhancing cellular metabolism and energy production via the glycolytic pathway and subsequent oxidative phosphorylation.
Intravenous infusion, 500-1000 mL (50-100 g dextrose) as a single dose, rate determined by clinical condition; typical maintenance 100-125 mL/h.
Intravenous infusion. Typical adult dose is 500-1000 mL of 7.7% dextrose solution infused at a rate of 100-200 mL/hour, titrated to clinical response and serum glucose levels.
None Documented
None Documented
The metabolic half-life of glucose is 1.5–2.5 hours; however, the plasma half-life of infused dextrose is approximately 1.5–2 hours, with clinical context indicating that doses >0.5 g/kg/hour can exceed oxidative capacity, leading to hyperglycemia.
30-60 minutes for blood glucose to return to baseline after infusion cessation; clinical context: rapid metabolism via glycolysis.
Glucose is primarily metabolized via glycolysis and oxidative phosphorylation to CO2 and water; less than 5% is excreted unchanged in urine under normal conditions. In hyperglycemia with glycosuria, up to 50% may be lost renally.
Renal: 100% as CO2 and water; no unchanged dextrose excreted in urine under normal conditions.
Category C
Category C
Intravenous Fluid
Intravenous Fluid